Hanmi Pharmaceutical Q3 Revenue Tops KRW 377.4 Billion; Operating Profit Down 31%
Cumulative Revenue Reaches KRW 1.2376 Trillion in the First Three Quarters
Prescription Growth Continues for Key Drugs Including Rosuzet
Beijing Hanmi Recovers; Hanmi Fine Chemical Returns to Profitability
Hanmi Pharmaceutical surpassed KRW 1.2 trillion in cumulative revenue for the first three quarters of this year, boosted by expanded prescriptions of its flagship prescription medicines. Key products such as Rosuzet led growth, while results also improved at its Chinese subsidiary and its affiliate specializing in active pharmaceutical ingredients. However, third-quarter operating profit fell by about 30% year on year.
Hanmi Pharmaceutical disclosed on October 27 that it recorded consolidated revenue of KRW 377.4 billion, operating profit of KRW 37.8 billion and net profit of KRW 14 billion in the third quarter of this year. Revenue rose 4.2% year on year, while operating profit and net profit fell 31.3% and 69.1%, respectively.
Hanmi Pharmaceutical said, "Operating profit and net profit declined from the previous quarter due to a base effect from the one-time recognition of an upfront payment under the sonofepegutide technology transfer agreement. However, the company is maintaining stable growth, supported by solid growth in key products such as Rosuzet, a gradual recovery at Beijing Hanmi Pharmaceutical following its strategy to respond to China's centralized procurement system, and improved profitability at Hanmi Fine Chemical."
Hanmi Pharmaceutical's cumulative third-quarter outpatient prescription sales, based on UBIST data, reached KRW 783.5 billion. Third-quarter outpatient prescription sales of Rosuzet, a combination drug for dyslipidemia, rose 10.6% year on year to KRW 65.2 billion. The company's other sales included KRW 38.2 billion from its Amosartan Family hypertension product line and KRW 15.2 billion from its Esomezol Family gastroesophageal reflux disease product line.
Beijing Hanmi Pharmaceutical, the company's Chinese subsidiary, recorded revenue of KRW 79.3 billion in the third quarter of this year. It showed a gradual recovery as it pursued sales strategies including strategic bidding and expanded supply volumes to respond to China's centralized procurement system. The company said it has suspended new transactions with distributors of concern until Beijing Hanmi collects its receivables, and is further strengthening its internal control system.
Hanmi Fine Chemical, an affiliate specializing in active pharmaceutical ingredients (APIs), recorded third-quarter revenue of KRW 22.8 billion, up 32.6% year on year. Despite intensifying competition in the market for Cepha-class antibiotics, operating profit and net profit returned to the black, supported by an increase in new orders for high-margin contract development and manufacturing (CDMO) services.
In research and development (R&D), Hanmi is advancing around 30 innovative drug pipeline candidates in areas including obesity and metabolic disorders, rare diseases and cancer. It is strengthening its global technological competitiveness through a differentiation strategy that incorporates new modalities (therapeutic approaches). With the launch of Epe, a GLP-1 obesity drug developed using Hanmi's proprietary technology and the first of its kind developed in Korea, approaching, the company is building a full-cycle portfolio of personalized obesity treatments through its H.O.P. Project, which will introduce next-generation obesity drugs in stages.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Hanmi Pharmaceutical official said, "As a leading R&D-focused pharmaceutical company in Korea, we are continuing to innovate to strengthen our core competitiveness and secure future growth engines. We will continue to focus our capabilities on new drug research and development and work to enhance shareholder value to achieve sustainable growth."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.